Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan
· Delayed Price · Currency is TWD 26.15
-0.20 (-0.76%)
Apr 29, 2026, 12:38 PM CST
Orient Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,400 | 1,223 | 889.91 | 511.86 | 463.34 | Upgrade
|
| Revenue Growth (YoY) | 14.52% | 37.41% | 73.86% | 10.47% | 12.46% | Upgrade
|
| Cost of Revenue | 609.66 | 571.26 | 421.25 | 356.51 | 320.67 | Upgrade
|
| Gross Profit | 790.72 | 651.56 | 468.67 | 155.35 | 142.67 | Upgrade
|
| Selling, General & Admin | 443.73 | 373.93 | 341.01 | 67.83 | 56.45 | Upgrade
|
| Research & Development | 79.93 | 103.72 | 99.9 | 129.25 | 219.72 | Upgrade
|
| Operating Expenses | 529.66 | 493.65 | 444.35 | 197.09 | 276.16 | Upgrade
|
| Operating Income | 261.06 | 157.91 | 24.32 | -41.74 | -133.49 | Upgrade
|
| Interest Expense | -7.91 | -13.97 | -13.9 | -7.37 | -5.7 | Upgrade
|
| Interest & Investment Income | 4.34 | 3.62 | 1.68 | 1.09 | 0.52 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.83 | 5.25 | 1.07 | 5.31 | 1.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.85 | 10.31 | 9.79 | 1.72 | 37.33 | Upgrade
|
| EBT Excluding Unusual Items | 253.51 | 163.12 | 22.95 | -40.99 | -100.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.22 | - | -0.04 | -0.13 | - | Upgrade
|
| Asset Writedown | -8.65 | - | - | - | -10 | Upgrade
|
| Other Unusual Items | - | - | 0.01 | 0.01 | - | Upgrade
|
| Pretax Income | 244.65 | 163.12 | 22.92 | -41.11 | -110.09 | Upgrade
|
| Income Tax Expense | 36.21 | 55.75 | 0.64 | -12.35 | -7.44 | Upgrade
|
| Net Income | 208.44 | 107.37 | 22.29 | -28.76 | -102.65 | Upgrade
|
| Net Income to Common | 208.44 | 107.37 | 22.29 | -28.76 | -102.65 | Upgrade
|
| Net Income Growth | 94.12% | 381.76% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 230 | 223 | 223 | 187 | 187 | Upgrade
|
| Shares Outstanding (Diluted) | 230 | 223 | 223 | 187 | 187 | Upgrade
|
| Shares Change (YoY) | 3.32% | - | 19.27% | -0.00% | 10.40% | Upgrade
|
| EPS (Basic) | 0.90 | 0.48 | 0.10 | -0.15 | -0.55 | Upgrade
|
| EPS (Diluted) | 0.90 | 0.48 | 0.10 | -0.15 | -0.55 | Upgrade
|
| EPS Growth | 87.89% | 381.76% | - | - | - | Upgrade
|
| Free Cash Flow | 324.04 | 168.38 | -157.1 | -17.01 | -120.1 | Upgrade
|
| Free Cash Flow Per Share | 1.41 | 0.76 | -0.70 | -0.09 | -0.64 | Upgrade
|
| Gross Margin | 56.46% | 53.28% | 52.66% | 30.35% | 30.79% | Upgrade
|
| Operating Margin | 18.64% | 12.91% | 2.73% | -8.15% | -28.81% | Upgrade
|
| Profit Margin | 14.88% | 8.78% | 2.50% | -5.62% | -22.16% | Upgrade
|
| Free Cash Flow Margin | 23.14% | 13.77% | -17.65% | -3.32% | -25.92% | Upgrade
|
| EBITDA | 375.51 | 272.67 | 138.97 | 12.43 | -82.31 | Upgrade
|
| EBITDA Margin | 26.82% | 22.30% | 15.62% | 2.43% | -17.76% | Upgrade
|
| D&A For EBITDA | 114.45 | 114.76 | 114.65 | 54.17 | 51.18 | Upgrade
|
| EBIT | 261.06 | 157.91 | 24.32 | -41.74 | -133.49 | Upgrade
|
| EBIT Margin | 18.64% | 12.91% | 2.73% | -8.15% | -28.81% | Upgrade
|
| Effective Tax Rate | 14.80% | 34.18% | 2.77% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.